Therapeutics/Diagnostics News

A microsimulation model showed a reduction in colorectal cancer disease burden and mortality when screening for CRC was initiated at ages 45 years or 40 years, which also added life-years to the population at a comparable health care cost.

Topline findings from the phase 2a DUET trial showed that Tern Pharmaceuticals’ oral thyroid hormone receptor-beta agonist achieved significant reductions in liver fat content among patients with nonalcoholic steatohepatitis.

In the latest installment of our diversity, equity and inclusion video series with ASGE, Anna H. Owings, DO, discusses racial disparities in treatment initiation and response in patients with inflammatory bowel disease.

The small-interfering RNA JNJ-3989 induced a dose-dependent response for meeting nucleos(t)ide analogue-stopping criteria in patients with chronic hepatitis B virus infection, although hepatitis B surface antigen seroclearance was rare.

In a Healio video exclusive, Lindy Bancke, PharmD, outlines results from the “largest safety evaluation to date” for Rebyota, the first FDA-approved, microbiota-based treatment for prevention of recurrent Clostridioides difficile infection.

Veterans who declined participation in a colorectal cancer screening trial more often preferred noninvasive testing over colonoscopy, a preference that increased over time and was especially evident among those in the western United States.

A new clinical practice update from the AGA highlights the value of physical examination, effective communication and integrated care in the diagnosis and management of patients with belching, abdominal bloating or distention.

Benralizumab induced histological remission at 12 weeks in more than three-fourths of patients with eosinophilic gastritis, although other biomarkers of disease persisted, according to data in The Lancet Gastroenterology & Hepatology.

Video capsule endoscopy and double-balloon enteroscopy were safe and effective in the management of patients with indications other than suspected small bowel bleeding, including celiac disease and Crohn’s disease, researchers reported.

The FDA granted 510(k) clearance to Becton Dickinson’s updated Alaris infusion pump, allowing the company to resume distribution of its system while remediating or replacing older Alaris devices still being used in the U.S. market.